medigraphic.com
ISSN 0016-3813 (Print)

2017, Number 2

<< Back Next >>

Gac Med Mex 2017; 153 (2)

Results of the First Mexican Consensus of Vaccination in the Adult

Gutiérrez-Robledo LM, Caro-López E, Guerrero-Almeida ML, Dehesa-Violante M, Rodríguez-Noriega E, García-Lara JM, Medina-López Z, Báez-Saldaña R, Díaz-López E, Avila-Fematt FMG, Betancourt-Cravioto M, Garcia-Garcia L

Language: Spanish
References: 107
Page: 190-204
PDF size: 176.94 Kb.


ABSTRACT

For years our efforts have been focused on vaccination during childhood. Today we know that this is not enough to ensure health in the rest of the life. Childhood is as important as any other stage and, therefore, vaccination must be permanent and differentiated, according to our age, throughout life. Introducing a life course perspective in vaccination programs, with emphasis on adult vaccination, particularly in older adults, offers us the opportunity to review the performance of health programs, actions, and services in the field of immunization, as well as strengthening health promotion actions. In this context, the first Mexican Consensus on Adult Vaccination was carried out in a joint effort of the National Institute of Geriatrics, bringing together a group of specialists who worked on three central objectives: establishing vaccination guidelines throughout the life course, with emphasis on new vaccines; defining priority groups according to their risk factors; and contributing to the effort to promote healthy aging.


REFERENCES

  1. Informe Mundial sobre el Envejecimiento y la Salud. Ginebra: Organización Mundial de la Salud. Ginebra;2015. http://apps.who.int/iris/bitstream/ 10665/186471/1/WHO_FWC_ALC_15.01_spa.pdf?ua=1

  2. Cortez-Alcalá R, Luna-Guzmán P, Grajales-Muñiz C, Ortiz-García F, et al. Grupo Técnico Interinstitucional del Comité Nacional para la Vigilancia Epidemiológica (CONAVE). Manual de procedimientos estandarizados para la vigilancia epidemiológica de las enfermedades prevenibles por vacunación. Dirección General de Epidemiología. Secretaría de Salud. Septiembre de 2012.

  3. Gutiérrez Robledo LM, Garcia Garcia ML. Editores. Vacunación en el adulto mayor: perspectiva de curso de vida. Academia Nacional de Medicina de México. ISBN 978-607-443-565-8 Editorial Intersistemas CDMX, México 2015

  4. 4 WHO. Increasing RI Coverage by Reducing Missed Opportunities for Vaccination http://www.who.int/immunization/global_vaccine_action_ plan/SAGE_GVAP_Assessment_Report_2016_ES.pdf?ua=1

  5. O.M.S. Grupo de expertos de la OMS en asesoramiento estratégico sobre inmunización 2016. Examen a mitad de ejecución del plan de acción mundial sobre vacunas. http://www.who.int/immunization/global_ vaccine_action_plan/SAGE_GVAP_Assessment_Report_2016_ES.pdf? ua=1

  6. Hara M, Okada K, Yamaguchi Y, et al. Immunogenicity and safety after booster vaccination of diphtheria, tetanus, and acellular pertussis in young adults: an open randomized controlled trial in Japan. Clin Vacc Immunol. 2013;20:1799-804.

  7. Águas R, Goncalves G, Gomes MGM. Pertussis: increasing disease as a consequence of reducing transmission. Lancet Infect Dis. 2006;6:112-7.

  8. Quishui H, Mersola J. Factors contributing to pertussis resurgence. Future Microbiol. 2008;3:329-39.

  9. The Joint Commission. Tdap vaccination strategies for adolescents and adults, including health care personnel. Strategies from research and practice. Disponible en: https://www.jointcommission.org/assets/1/6/ Tdap_Monograpgh.pdf

  10. Kim D, Bridges CB, Harriman K. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older: United States, 2015. Ann Inter Med. 2015;162:214-24.

  11. Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353:1555-63.

  12. Wei SC, Tatti K, Cushing K, et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis. 2010;51:315-21.

  13. Muñoz FM, Bond NH, Maccato M, et al. Safety and immunogenicity of tetanus, diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA. 2014;311:1760-9.

  14. Koepke R, Kahn D, Petit A, et al. Centers for Disease Control and Prevention (CDC). Pertussis and influenza vaccination among insured pregnant women – Wisconsin, 2013-2014. MMWR Morb Mortal Wkly Rep. 2015;64:746-50.

  15. Farhat F, Wortmann G. Vaccinating adults who are pregnant, older, or immunocompromised, or have chronic kidney disease. Clev Clin J Med. 2015;82:341-7.

  16. Trucchi C, Zoppi G. Decennial diphtheria-tetanus adult boosters: are they really necessary? J Prev Med Hyg. 2015;56:E44-8.

  17. Hepatitis B. Centro de prensa de la OMS. Nota descriptiva No. 204, 2015.

  18. Hou J, Liu Z, Gu F. Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci. 2005;(1):50-7.

  19. Kao JH. Hepatitis B vaccination and prevention of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2015;29:907-17.

  20. Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol. 2007;211:144-56.

  21. Mendy M. Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose. PLOS One. 2013;8:1-9.

  22. Dehesa M. Hepatitis B. Rev Gastroenterol Mex. 2013;78(Supl 1):90-2.

  23. CDC. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011;60:1709-11.

  24. INEGI. Los adultos mayores en México. Perfil Sociodemográfico; 2005. p. 107.

  25. SS. NOM-036-SSA 2-2012. Prevención y control de enfermedades. Aplicación de vacunas, toxoides, faboterápicos (sueros) en SS, inmunoglobulinas en el humano.

  26. SS. Cartilla Nacional de Salud del Adulto Mayor, 2014.

  27. Michel JP. Coalition of advocates to vaccinate of Western European citizens aged 60 years and older. Aging Clin Exp Res. 2009:21:1-4.

  28. Cunningham AL, Breuer J, Dwyer DE, et al. The prevention and management of herpes zoster. MJA. 2008;188:171-6.

  29. Ultsch B, Weidermann F, Reinhold T, Siedler A, Krause G, Wichmann O. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res. 2013;13:359.

  30. Sanford M, Keating GM. Zoster vaccine (Zostavax®). A review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging. 2010;27:159-76

  31. Arnou R, Fiquet A, Thomas S, Sadorge C. Immunogenicity and safety of ZOSTAVAX® approaching expiry potency in individuals aged ≥ 50 years. Human Vaccines. 2011;7:1060-5.

  32. Cohen JI. Herpes zoster. N Engl J Med. 2013;369:255-63.

  33. Forbes H, Thomas SL, Langan SM. The epidemiology and prevention of herpes zoster. Curr Derm Rep. 2012;1:39-47.

  34. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and posherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-84.

  35. Aspinall R, Lang PO. Vaccine responsiveness in the elderly: best practice for the clinic. Expert Rev Vaccines 2014;13:885-94.

  36. Schmader K, Levin MJ, Gnann JW, et al. Efficacy, safety and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54:922-8.

  37. Pilkinton MA, Talbot HK. Update on vaccination guidelines for older adults. J Am Geriatr Soc. 2015;63:584-8.

  38. Baxter R, Nam TT, Hansen J, et al. Safety of ZostavaxTM - A cohort study in a managed care organization. Vaccine. 2012;30:6636-41.

  39. Información para prescribir amplia de Zostavax® (Oka/Merck), 30-04-2009.

  40. Advisory Committee Statement (ACS) – National Advisory Committee on Immunization (NACI). Update on the use of herpes zoster vaccine. January 2014. Disponible en: http://www.phac-aspc.gc.ca/naci-ccni/ hzv-vcz-eng.php

  41. Advisory Committee Statement. Statement on the recommended use of herpes zoster vaccine. CCDR RMTC 2010;36:ACS-1. Disponible en: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/10vol36/acs-1/index- eng.php

  42. Komara FA. Herpes zoster vaccination: benefits and barriers. JAOA. 2009;109(Suppl 2):522-4.

  43. Lal H, Cunningham AL, Godeauz O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087-96.

  44. Geier D, King PG, Geier MR. Influenza vaccine: review of effectiveness of the U.S. Immunization Program, and policy considerations. J Am Phys Surg. 2006;11:69-74.

  45. OPS-CDC. Protocolo genérico para la vigilancia de la influenza. Washington D.C. ; 2009. Disponible en: http://new.paho.org/hq/dmdocuments/ 2009/Protocolo_Gen_ESP.pdf

  46. Influenza. Documento técnico. Secretaría de Salud, México 2014. Disponible en: http://www.epidemiologia.salud.gob.mx/doctos/lineamientos/ influenza/documento_tecnico_influenza.pdf

  47. Solórzano-Santos F, Miranda-Novales MG. Influenza. Bol Med Hosp Infant Mex. 2009;66:461-73.

  48. Lade KS, Sawant SD, Singh MC. Review on influenza with special emphasis on swine flu. Int J Curr Pharm Res. 2011;3:97-107.

  49. Prevención, diagnóstico y tratamiento de la influenza estacional. Guía de evidencias y recomendaciones. México: Secretaría de Salud, CENETEC- Salud; 2015. Fecha de publicación 2 de julio de 2015. Disponible en: www.cenetec.salud.gob.mx/contenidos/gpc/catalogoMaestro

  50. Aviso Epidemiológico de Influenza. CONAVE/01/2016/Influenza. Actualización de la situación de influenza durante la temporada 2015-2016. Comité Nacional para la Vigilancia Epidemiológica, 10 de febrero de 2016. Disponible en: https://www.gob.mx/cms/uploads/attachment/ file/56389/Aviso_Epi_influenza_130216.pdf

  51. Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med. 2010;363:2036-44.

  52. Kuri-Morales P, Galván F, Cravioto P, et al. Mortalidad en México por influenza y neumonía (1990-2005). Salud Publica Mex. 2006;48:379-84.

  53. Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007;357:1373-81.

  54. Treanor JJ, Talbot HK, Ohmit SE, et al. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis. 2012;55:951-9.

  55. Vacunas autorizadas en México incluyendo fichas técnicas. Comisión Federal para la Protección contra Riesgos Sanitarios. Actualización del 27 de julio de 2015. Secretaría de Salud, 2015.

  56. Cartillas Nacionales de Salud. Secretaría de Salud, México 2015. (Consultado el 15 de enero de 2016.) Consultado el 1 de abril de 2017. Disponible en: http://www.gob.mx/salud/articulos/cartillas-nacionales-de-salud-12270

  57. Atkinson W, Hamborsky J, McIntyre L, Wolfe S, editores. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine- preventable diseases. 10th ed. Washington DC: Public Health Foundation; 2007. p. 271-82.

  58. OMS. Meningococcal vaccines: position paper, November 2011. Wkly Epidemiol Rec. 2011;47:521-39.

  59. CDC. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013;62:1-28.

  60. Kim DK, Bridges CB, Harriman KH. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older: United States, 2015. Ann Intern Med. 2015;162:214-25.

  61. Consejo Nacional de Vacunación. Vacuna antimeningocócica. En: Manual de Vacunación 2008-2009. México: Secretaría de Salud; 2008. p. 158-63.

  62. Almirall J, Bolíbar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J. 2000;15:757-63vv

  63. Millett ER, Quint JK, Smeeth L, et al. Incidence of community-acquired lower respiratory tract infections and pneumonia among older adults in the United Kingdom: a population-based study. PLoS One. 2013;8:e75131.

  64. Báez-Saldaña R, Gómez-Zamora C, López-Elizondo C, et al. Neumonía adquirida en la comunidad. Revisión y actualización con una perspectiva orientada a la calidad de la atención médica. Neumol Cir Torax. 2013;72(Supl 1):6-43.

  65. Shapiro ED, Berg AT, Austrian R, et.al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325:1453-60.

  66. Ansaldi F, Orsi A, Trucchi C, et al. Potential effect of PCV13 introduction on emergency department accesses for lower respiratory tract infections in elderly and at risk adults. Hum Vaccin Immunother. 2015;11:166-71.

  67. Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine- naïve adults. Vaccine. 2013;31:3577-84.

  68. Kim DD, Bridges CB, Harriman K. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older: United States, 2016. Ann Intern Med. 2016;164:184-94.

  69. Lindsey NP, Lehman JA, Staples JE, Fischer M. West Nile virus and other nationally notifiable arboviral diseases – United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64:929-34.

  70. Consejo Nacional de Vacunación. Vacuna polisacárida contra neumococo. En: Manual de Vacunación 2008-2009. México: Secretaría de Salud; 2008. p. 106-10.

  71. GlaxoSmithKline Vaccine HPV 007 Study Group; Romanowski B, de Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of human papillomavirus (HPV)-16/18-adjuvante vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009;374:1975-85.

  72. Dochez C, Bogers JJ, Verhelst R, Rees H. HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine. 2014;32:1595-601.

  73. Schwars TF. Clinical update of the AS04-adjuvanted human papillomavirus- 16/18 cervical cancer vaccine, Cervarix. Springer Healthcare; septiembre 2009.

  74. Vanegas VA, Rubio AI, Bedoya AM, Sánchez GI. Estructura molecular y antigénica de la vacuna contra el virus del papiloma humano 16 (VPH 16). Acta Biol Colomb. 2008;13:37-48.

  75. Lizano-Soberón M, Carrillo-García A, Contreras Paredes A. Infección por virus del papiloma humano: epidemiología, historia natural y carcinogénesis. Cancerología. 2009;4:205-16.

  76. Bathia N, Lynde C, Vender R, Bourcier M. Understanding genital warts: epidemiology, pathogenesis, and burden of disease of human papillomavirus. J Cutan Med Surg. 2013;17(Suppl 2):S47-54.

  77. Draper E, Bissett SL, Howell-Jones R, et al. A randomized, observer-blinded inmunogenicity trial of Cervarix® and Gardasil® human papillomavirus vaccines in 12-15 year old girls. www.plosone.org. 2013;8:e61825.

  78. Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines. 2009;8:1663-79.

  79. Canada Communicable Disease Report. Update on human papillomavirus (HPV) vaccines. CCDR. 2012;38(ACS-1).

  80. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis. 2006;1994:1044-57.

  81. Maleki Z. Human papilloma virus vaccination: review article and an update. World J Obst Gynecol. 2016;5:16-27.

  82. Campinis Mart M, Moraga Llop FA. Nuevas perspectivas de la vacunación frente al virus del papiloma humano en la mujer adulta. p.p. 160 -166 y Taller de casos prácticos: Vacunación frente al virus del Papiloma humano en pacientes con infección por el virus de la Inmunodeficiencia humana pp. 255-260 en: Vacunas 2015. http://www.vhebron.net/ es/medicina-preventiva

  83. Declaración de la FIGO sobre la seguridad de la vacunación del VPH, 2 de agosto de 2013. p. 1-6. Disponible en: http://www.femecog.org.mx/ cerca%20de%20ti/VI-FIGO%20Statement.pdf

  84. Daron F, Samakoses R, Block SL, et.al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics. 2014;134:e657-65.

  85. Wright TC, Huh WK, Monk BJ, Smith JS, Ault K, Herzog TJ. Age considerations when vaccinating against HPV. Gynecol Oncol. 2008;109(2 Suppl):S40-7.

  86. Stanley M, Wheeler C. Primary end-points for prophylactic HPV vaccine trials. Chapter 6. HPV VLP vaccines-alternative dosage schedules and immunization in immunosuppressed subjects. Disponible en: https:// www.ncbi.nlm.nih.gov/books/NBK304972/

  87. Lazcano-Ponce E, Stanley M, Muñoz N, et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine. 2014;32:725-32.

  88. Programa de Vacunación Universal y Semanas Nacionales de Salud. México: Secretaría de Salud, Lineamientos generales; 2015.

  89. Paavonen J, Naud P, Salmerón J, et al. HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009 Jul 25;374(9686):301-14.

  90. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immnunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009;5:705-19.

  91. FDA News Relase. FDA licenses new vaccine for prevention of cervical cancer and other diseases in females by human papillomavirus. June 8, 2006. Disponible en: http://www.fda-gov/bbs/topics/NEWS/2006/ NEW01385.

  92. Giuliano AR, Isaacs-Soriano K, Torres BN, et al. Immunogenicity and safety of Gardasil among mid-adult aged men (24-45 years) – The MAM Study. Vaccine. 2015;33:5640-6.

  93. Dantés HG, Farfán-Ale JA, Sarti E. Epidemiological trends of dengue disease in Mexico (2000-2011): a systematic literature search and analysis. PLoS Negl Trop Dis. 2014;8:e3158.

  94. World Health Organization. Global strategy for dengue prevention and control. 2012-2020. Disponible en: http://apps.who.int/iris/bitstre am/10665/75303/1/9789241504034_eng.pdf

  95. Liu Y, Zhou J, Yu Z, et al. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties. BMC Microbiol. 2014;14:233.

  96. Arellano C, Castro L, Díaz-Caravantes RE, et al. Knowledge and beliefs about dengue transmission and their relationship with prevention practices in Hermosillo, Sonora. Front Public Health. 2015;3:142.

  97. Secretaría de Salud. Dirección General de Epidemiología – Panorama epidemiológico de fiebre por dengue y fiebre hemorrágica por dengue – Semana epidemiológica 52. 4 de enero de 2016. Disponible en: http:// www.epidemiologia.salud.gob.mx/doctos/panodengue/PANORAMAS_ 2015/Pano_dengue_sem_52_2015.pdf

  98. Secretaría de Salud. Guías prácticas clínicas. Manejo del dengue no grave y el dengue grave. 11 de diciembre de 2015. Disponible en: http:// www.gob.mx/cms/uploads/attachment/file/37875/SSA_151_08_EyR_ Dengue_170310.pdf

  99. Valencia-Mendoza A, Danese-dlSantos LG, Sosa-Rubí SG, Aracena-Genao B. Costo-efectividad de prácticas en salud pública: revisión bibliográfica de las intervenciones de la Iniciativa Mesoamericana de Salud. Salud Publica Mex. 2011;53(Supl 3):S375-85.

  100. Jelitha R, Nirmalatiban P, Nyanamalar S, Cabriz MG. Descriptive review of safety, reactogenicity and immunogenicity of dengue vaccine clinical trials, 2003-2013. Med J Malaysia. 2015;70:67-75.

  101. McArthur MA, Sztein MB, Edelman R. Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert Rev Vaccines. 2013;12:933-53.

  102. Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384:1358-65.

  103. Hernández-Ávila M, Lazcano-Ponce E, Hernández-Ávila JE, et al. Análisis de la evidencia sobre eficacia y seguridad de la vacuna de dengue CYD-TDV y su potencial registro e implementación en el Programa de Vacunación Universal de México. Salud Publica Mex. 2016;58:71-83.

  104. Comisión Federal para la Protección contra Riesgos Sanitarios. México aprueba la primera vacuna contra el virus del dengue a nivel mundial. Comunicado de prensa 106/15. 9 de diciembre de 2015. Disponible en: http://www.cofepris.gob.mx/Documents/NotasPrincipales/09122015.pdf

  105. Summary of the April 2016 Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE). Ginebra, Suiza. Disponible en: http:// www.who.int/immunization/sage/meetings/2016/april/SAGE_April_2016_ Meeting_Web_summary.pdf?ua=1

  106. Hadinegoro SR, Arredondo-García JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373:1195-206.

  107. Villar L, Dayan GH, Arredondo-García JL. Tornieporth N, Saville M, Noriega F; CYD15 Study Group. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015 Jan 8;372(2):113-23. doi: 10.1056/NEJMoa1411037. Epub 2014 Nov 3.




2020     |     www.medigraphic.com